3 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
Follow Cadonilimab: new trials by email Literature Review of Cadonilimab trials Research Report on Cadonilimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer Cadonilimab - Triple-negative Breast Cancer, Cadonilimab | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 27 | 2024-05-01 | 2025-05-20 |
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab - Nanoliposomal Irinotecan, Cadonilimab | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-04-17 | 2024-12-24 |
| Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer Cadonilimab + bevacizumab + FOLFOX - Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma | Phase 2 | Recruiting | Fudan University | 53 | 2024-01-01 | 2024-01-23 |
Colorectal Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (2) · Neoplasms by Site (2) · Breast Diseases (1) · Breast Neoplasms (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Rectal Diseases (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Bevacizumab (1) · Folfox protocol (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (3)
Yanxia Zhao, PhD (1)